References
- FDA, Draft Guidance for Industry: Stability Testing of Drug Substances and Drug Products, FDA, Rockville 1998.
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A (R2), Step 5, ICH Geneva, Aug. 2003.
- H.R. Brunner, The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview, J. Hum. Hypertens. 16 (2002) S13-S16; DOI: 10.1038/sj/jhh/1001391.
- H. Koike, T. Konse, T. Sada, T. Ikeda, S. Hyogo, D. Hinman, H. Saito, and H. Yanagisawa, Olmesartan medoxomil, a novel potent angiotensin II blocker, Ann. Rep. Snakyo Res. Lab. 55 (2003) 1-91.
- D.E. Mire, T.N. Silfani and M.K. Pugsley, A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker, J. Cardiovasc. Pharmacol. 46 (2005) 585-593; DOI: 10.1097/01.fjc.0000180902.78230.fd.
- H. Koike, T. Sada and M. Mizuno, In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist, J. Hypertens. 19 (Suppl) (2001) S3-S14.
- G.T. Warner and B. Jarvis, Olmesartan medoxomil, Drugs 62 (2002) 1345-1353.
- O. Sagirli, A. Önal, S.E. Toker and D. Sensoy, Simultaneous HPLC analysis of olmesartan and hydrochlorothiazide in combined tablets and in vitro dissolution studies, Chromatographia 66 (2007) 213-218; DOI: 10.1365/s10337-007-0304-9.
- K. Yoshihara, Y. Gao, H. Shiga, D.R. Wada and M. Hisaoka, Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients, Clin. Pharmacokin., 44 (2005) 1329-1342.
- H. Nakamura, T. Inoue, N. Arakawa, Y. Shimizu, Y. Yoshigae, I. Fujimori, E.H. Nakamura, T. Inoue, N. Arakawa, Y. Shimizu, Y. Yoshigae, I. Fujimori, E. Shimakawa, T. Toyoshi and T. Yokoyama, Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models, Eur. J. Pharmacol. 512 (2005) 239-246; DOI: 10.1016/j.ejphar.2005.02.047.
- V.V. Vaidya, S.M. Roy, S.M. Yetal, S.S. Joshi and S.A. Parekh, LC-MS-MS determination of olmesartan in human plasma, Chromatographia 67 (2008) 147-150; DOI: 10.1365/s10337-007-0453-x.
- L. Dongyang, H. Pei, M. Nobuka, L. Xiaoming, L. Li and J. Ji, Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry, J. Chromatogr. B 856 (2007) 190-197; DOI: 10.1016/j.jchromb.2007.05.049.
- N.J. Shah, B.N. Suhagia, R.R. Shah and N.M. Patel, Development and validation of a simultaneous HPTLC method for the estimation of olmesartan medoxomil and hydrochlorothiazide in tablet dosage form, Indian J. Pharm. Sci. 69 (2007) 834-836; DOI: 10.4103/0250-474X.39447.
- C. Mustafa and A. Sacide, Development of a CZE method for the determination of olmesartan medoxomil in tablets, Chromatographia 66 (2007) 929-933; DOI: 10.1365/s10337-007-0424-2.
- T. Murakami, H. Konno, N. Fukutsu, M. Onodera, T. Kawasaki and F. Kusu, Identification of a degradation product in stressed tablets of olmesartan medoxomil by the complementary use of HPLC hyphenated techniques, J. Pharm. Biomed. Anal. 47 (2008) 553-559; DOI: 10.1016/j.jpba.2008.02.021.
- International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guidelines, Validation of Analytical Procedure: Text and Methodology Q2 (R1), Current Step 4 version, ICH Geneva, Nov. 2005.
- G.W. Ewing, Instrumental Methods of Chemical Analysis, 5th ed., Lippincott-Raven, Philadelphia 1995, pp. 484-486.
- Z. Zhao, Q. Wang, E.W. Tsai, X.Z. Qin and D. Ip, Identification of losartan degradates in stressed tablets by LC-MS and LC-MS/MS, J. Pharm. Biomed. Anal. 20 (1999) 129-36; DOI: 10.1016/S0731-7085(99)00004-7.